Stock Movers

Steel Stocks Movers; Bristol Myers Deal; BYD Downswing

Jun 2, 2025
The podcast discusses the potential impact of President Trump's proposed steel and aluminum tariff hikes, with US Steel's stock dropping while Cleveland Cliffs enjoys a bump. Concerns about BYD's aggressive price cuts stirring government scrutiny highlight challenges in the Chinese EV market. In the pharmaceutical arena, Bristol Myers Squibb clinches a massive deal with BioNTech for a promising cancer drug, signaling a notable investment in future treatments. The conversation also touches on the volatility of Tesla's stock in the midst of changing market dynamics.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Trump's Tariff Hike Impact

  • President Trump plans to increase steel and aluminum tariffs to 50%, up from 25%, to protect American workers.
  • This announcement hurt U.S. Steel shares but boosted competitors like Cleveland Cliffs and other aluminum stocks.
INSIGHT

BYD Price Cuts Cause Concerns

  • BYD's price cuts are driving strong sales but causing government concern over sustainability and quality.
  • Chinese authorities warn that aggressive discounting hurts profit margins and the reputation of 'Made in China'.
INSIGHT

Big Pharma Bets on Cancer Drugs

  • Bristol Myers Squibb agreed to pay BioNTech up to $11.1 billion for licensing a next-gen cancer drug.
  • This reflects a trend of pharma companies investing heavily in immuno-oncology treatments, anticipating huge market growth.
Get the Snipd Podcast app to discover more snips from this episode
Get the app